KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

A pathomics model for predicting response to chemo-immunotherapy in lung squamous cell carcinoma: A multicenter study.

Dongying Wang, Shuai Mu, Minghui Zhang, Guangyu Tao, Shuyuan Wang, Yinchen Shen, Guanxi Xiao, Xueyan Zhang, Baohui Han, Lei Cheng, Hua Zhong, Wei Nie

Lung Cancer 211 108881

PMID41421034
PMCID-
DOI10.1016/j.lungcan.2025.108881
发表日期2025-12-20
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

BACKGROUND: The identification of lung squamous cell carcinoma (LUSC) patients who may benefit from first-line chemo-immunotherapy (CIT) remains a challenge. This study aimed to develop a pathomics model to predict the T cell-inflamed gene-expression profile (GEP) status and validate its utility in identifying patients who derive survival benefit from CIT. METHODS: The pathomics model was developed using whole-slide images and RNA-sequencing data from The Cancer Genome Atlas (TCGA) LUSC cohort (n = 334) to predict the GEP status and generate a pathomics score (PS). The predictive value of PS was validated in a prospective, multicenter trial (AK105-302, n = 267) by assessing its interaction with treatment (CIT vs. chemotherapy) for progression-free survival (PFS) and overall survival (OS). Two additional independent cohorts (n = 82 and n = 50) were used for external validation. RESULTS: The pathomics model accurately predicted GEP status, achieving area under the curve (AUC) values of 0.80 and 0.71 in the TCGA training and validation sets, respectively. In the AK105-302 cohort, significant interactions were identified between PS and treatment modalities for both PFS (interaction p = 0.011) and OS (interaction p < 0.001). Patients with high PS who received CIT exhibited significantly prolonged PFS (hazard ratio [HR]: 0.31, 95 % confidence interval [CI]: 0.21-0.48, p < 0.001) and OS (HR: 0.30, 95 % CI: 0.18-0.50, p < 0.001) compared to high PS patients receiving chemotherapy. However, this survival benefit was not observed in the low-PS patients. These findings were corroborated in two independent clinical cohorts. Furthermore, biological assessments revealed a significant association between high PS and an immune-hot tumor microenvironment. CONCLUSION: We developed a GEP-based pathomics model that provides a practical, cost-effective strategy to identify patients most likely to derive superior survival benefit from first-line CIT over chemotherapy alone.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。